X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs SHASUN PHARMA - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON SHASUN PHARMA BIOCON /
SHASUN PHARMA
 
P/E (TTM) x 41.0 123.9 33.1% View Chart
P/BV x 7.1 8.5 83.5% View Chart
Dividend Yield % 0.2 0.2 69.7%  

Financials

 BIOCON    SHASUN PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
SHASUN PHARMA
Mar-14
BIOCON /
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,18894 1,261.1%   
Low Rs30546 668.9%   
Sales per share (Unadj.) Rs68.7214.2 32.1%  
Earnings per share (Unadj.) Rs7.65.3 141.5%  
Cash flow per share (Unadj.) Rs14.015.8 88.3%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %0.11.4 9.4%  
Book value per share (Unadj.) Rs86.353.3 161.9%  
Shares outstanding (eoy) m600.0056.62 1,059.7%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.90.3 3,328.3%   
Avg P/E ratio x98.913.1 754.6%  
P/CF ratio (eoy) x53.44.4 1,209.4%  
Price / Book Value ratio x8.61.3 659.7%  
Dividend payout %13.218.7 70.7%   
Avg Mkt Cap Rs m447,9003,958 11,317.1%   
No. of employees `0006.1NA-   
Total wages/salary Rs m9,3112,164 430.4%   
Avg. sales/employee Rs Th6,705.8NM-  
Avg. wages/employee Rs Th1,514.2NM-  
Avg. net profit/employee Rs Th736.9NM-  
INCOME DATA
Net Sales Rs m41,23412,127 340.0%  
Other income Rs m2,062229 899.1%   
Total revenues Rs m43,29612,356 350.4%   
Gross profit Rs m8,2911,009 821.7%  
Depreciation Rs m3,851594 648.8%   
Interest Rs m615415 148.2%   
Profit before tax Rs m5,887230 2,562.9%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,569-73 -2,157.6%   
Profit after tax Rs m4,531302 1,499.7%  
Gross profit margin %20.18.3 241.7%  
Effective tax rate %26.7-31.7 -84.2%   
Net profit margin %11.02.5 441.1%  
BALANCE SHEET DATA
Current assets Rs m41,4866,884 602.6%   
Current liabilities Rs m21,4138,456 253.2%   
Net working cap to sales %48.7-13.0 -375.6%  
Current ratio x1.90.8 238.0%  
Inventory Days Days6462 103.8%  
Debtors Days Days94108 87.6%  
Net fixed assets Rs m50,6614,970 1,019.3%   
Share capital Rs m3,000113 2,647.8%   
"Free" reserves Rs m48,8082,875 1,697.7%   
Net worth Rs m51,8083,020 1,715.4%   
Long term debt Rs m17,8981,817 984.8%   
Total assets Rs m99,89713,347 748.5%  
Interest coverage x10.61.6 680.6%   
Debt to equity ratio x0.30.6 57.4%  
Sales to assets ratio x0.40.9 45.4%   
Return on assets %5.25.4 95.9%  
Return on equity %8.710.0 87.4%  
Return on capital %9.613.3 72.3%  
Exports to sales %046.4 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs mNA1,728 0.0%   
Fx inflow Rs m12,0585,843 206.4%   
Fx outflow Rs m7,3482,173 338.1%   
Net fx Rs m4,7103,669 128.4%   
CASH FLOW
From Operations Rs m6,621398 1,665.2%  
From Investments Rs m-6,840-1,635 418.3%  
From Financial Activity Rs m-2,3971,309 -183.2%  
Net Cashflow Rs m-2,61271 -3,668.5%  

Share Holding

Indian Promoters % 40.4 39.2 103.1%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 3.6 233.3%  
FIIs % 10.7 17.6 60.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 39.6 50.3%  
Shareholders   109,995 20,750 530.1%  
Pledged promoter(s) holding % 0.0 12.3 0.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (4QFY18); Net Profit Up 19.8% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 19.8% YoY). Sales on the other hand came in at Rs 12 bn (up 25.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Apr 18, 2019 (Close)

TRACK BIOCON

BIOCON - VENUS REMEDIES COMPARISON

COMPARE BIOCON WITH

MARKET STATS